284 related articles for article (PubMed ID: 21437756)
1. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma.
Akutsu Y; Hanari N; Yusup G; Komatsu-Akimoto A; Ikeda N; Mori M; Yoneyama Y; Endo S; Miyazawa Y; Matsubara H
Ann Surg Oncol; 2011 Oct; 18(10):2946-51. PubMed ID: 21437756
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma.
He LR; Liu MZ; Li BK; Rao HL; Deng HX; Guan XY; Zeng YX; Xie D
Cancer Sci; 2009 Sep; 100(9):1591-6. PubMed ID: 19552757
[TBL] [Abstract][Full Text] [Related]
3. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
Sato Y; Motoyama S; Nanjo H; Ito S; Yoshino K; Sasaki T; Kuribayashi K; Nagaki Y; Imai K; Saito H; Minamiya Y; Ogawa J
Ann Surg Oncol; 2013 Sep; 20(9):3044-51. PubMed ID: 23645481
[TBL] [Abstract][Full Text] [Related]
4. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.
Motoyama S; Sugiyama T; Ueno Y; Okamoto H; Takasawa S; Nanjo H; Watanabe H; Maruyama K; Okuyama M; Ogawa J
Ann Surg Oncol; 2006 Dec; 13(12):1724-31. PubMed ID: 17009160
[TBL] [Abstract][Full Text] [Related]
5. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
Duong C; Greenawalt DM; Kowalczyk A; Ciavarella ML; Raskutti G; Murray WK; Phillips WA; Thomas RJ
Ann Surg Oncol; 2007 Dec; 14(12):3602-9. PubMed ID: 17896157
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
[TBL] [Abstract][Full Text] [Related]
8. Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma.
Kawasaki Y; Okumura H; Uchikado Y; Kita Y; Sasaki K; Owaki T; Ishigami S; Natsugoe S
Ann Surg Oncol; 2014 Jul; 21(7):2347-52. PubMed ID: 24599410
[TBL] [Abstract][Full Text] [Related]
9. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
[TBL] [Abstract][Full Text] [Related]
10. [Multivariate prognostic analysis for patients with unresectable esophageal carcinoma after concurrent chemoradiotherapy].
Chen EC; Liu MZ; Hu YH; Li QQ; Liu H; Cai L; Liu H; Lin HX; Huang Y; Wang HY; Cui NJ
Ai Zheng; 2005 Jun; 24(6):731-4. PubMed ID: 15946490
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
[TBL] [Abstract][Full Text] [Related]
12. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
Motoori M; Yano M; Ishihara R; Yamamoto S; Kawaguchi Y; Tanaka K; Kishi K; Miyashiro I; Fujiwara Y; Shingai T; Noura S; Ohue M; Ohigashi H; Nakamura S; Ishikawa O
Ann Surg Oncol; 2012 Jul; 19(7):2135-41. PubMed ID: 22302264
[TBL] [Abstract][Full Text] [Related]
13. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy.
Nomura M; Shitara K; Kodaira T; Hatooka S; Mizota A; Kondoh C; Yokota T; Takahari D; Ura T; Muro K
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):946-52. PubMed ID: 21362578
[TBL] [Abstract][Full Text] [Related]
15. Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy.
Saigusa S; Mohri Y; Ohi M; Toiyama Y; Ishino Y; Okugawa Y; Tanaka K; Inoue Y; Kusunoki M
Oncol Rep; 2011 Nov; 26(5):1069-74. PubMed ID: 21811761
[TBL] [Abstract][Full Text] [Related]
16. Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Shinoto M; Shioyama Y; Sasaki T; Nakamura K; Ohura H; Toh Y; Higaki Y; Yamaguchi T; Ohnishi K; Atsumi K; Hirata H; Honda H
Am J Clin Oncol; 2011 Aug; 34(4):362-6. PubMed ID: 20686402
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of high podoplanin expression after chemoradiotherapy in esophageal squamous cell carcinoma patients.
Chao YK; Chuang WY; Yeh CJ; Wu YC; Liu YH; Hsieh MJ; Cheng AJ; Hsueh C; Liu HP
J Surg Oncol; 2012 Feb; 105(2):183-8. PubMed ID: 22213642
[TBL] [Abstract][Full Text] [Related]
18. High orotate phosphoribosyltransferase gene expression predicts complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus.
Kajiwara T; Nishina T; Hyodo I; Moriwaki T; Endo S; Nasu J; Hori S; Matsuura B; Hiasa Y; Onji M
Oncology; 2009; 76(5):342-9. PubMed ID: 19307741
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
[TBL] [Abstract][Full Text] [Related]
20. Nonsurgical management of esophageal adenocarcinoma.
Gujral DM; Hawkins MA; Leonulli BG; Ashley S; Chau I; Cunningham D; Tait D
Clin Colorectal Cancer; 2011 Sep; 10(3):165-70. PubMed ID: 21855037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]